Universal Biosensors Signs deal with IQ Science to commercialise COVID-19 test
- Universal Biosensors (UBI) has entered into a global exclusive licence agreement with IQ Science for commercialisation of a SARS-CoV-2 N-Protein detection test
- The COVID-19 test will utilise UBI’s proprietary electrochemical strip and device technology designed to provide a result within 30 seconds from a small saliva sample
- UBI’s test method also has the potential to measure the relative viral load associated with a patient’s infection status
- UBI has been working with Dr Shalen Kumar of IQ Science for six months on the aptamer technology and the performance quality of IQ science products
- UniversalBiosensors shares are up 3.98 per cent to trade at 92 cents at 1:11 pm AEDT
